More on ISIS

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement

Upcoming Events

- Earnings (8/4/15)


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

ISIS Income Statement

Click line-items for a historical chart and %
Research and development revenue under collaborative agreements 61.89M
Licensing and royalty revenue 691K
Total revenue 62.58M
Research and development
General and administrative 7.47M
Total operating expenses 71.91M
Loss from operations -9.33M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc.
Investment income 845K
Interest expense -9.02M
Gain (loss) on investments, net 0
Loss before income tax expense
Income tax expense 789K
Net loss
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares)
Shares used in computing diluted net loss per share (in shares)